Halometasone/triclosan cream: (Sicorten plus). A study of clinical and allergological behaviour

P. D. Pigatto, M. Morelli, G. F. Altomare, C. Borghi

Research output: Contribution to journalArticle

Abstract

The clinical efficacy and safety, and the allergic potential of Sicorten Plus cream (0.05% halometasone, 1% triclosan) was investigated in an open trial of 21 days' duration in patients suffering from infected eczematous dermatitis. The cream was applied twice daily (morning and evening) in a thin layer with or without light occlusive dressing. The onset of therapeutic efficacy was observed, on average, after 9.5 days; subjective signs and symptoms significantly improved during the trial (ANOVA P <0.001). Most patients (92%) were completely cured in 21 days. Cosmetic acceptability of the cream was satisfactory. Only two patients dropped-out because of a severe burning sensation. No allergic reactions either with the ordinary patch test or the photopatch test were observed.

Original languageEnglish
Pages (from-to)222-226
Number of pages5
JournalClinical Trials Journal
Volume24
Issue number3
Publication statusPublished - 1987

Fingerprint

Triclosan
Occlusive Dressings
Patch Tests
Eczema
Cosmetics
Signs and Symptoms
Analysis of Variance
Hypersensitivity
Safety
Light
halometasone
Clinical Studies
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Halometasone/triclosan cream : (Sicorten plus). A study of clinical and allergological behaviour. / Pigatto, P. D.; Morelli, M.; Altomare, G. F.; Borghi, C.

In: Clinical Trials Journal, Vol. 24, No. 3, 1987, p. 222-226.

Research output: Contribution to journalArticle

@article{ba10e16e96ea45e785c2cba27f74849f,
title = "Halometasone/triclosan cream: (Sicorten plus). A study of clinical and allergological behaviour",
abstract = "The clinical efficacy and safety, and the allergic potential of Sicorten Plus cream (0.05{\%} halometasone, 1{\%} triclosan) was investigated in an open trial of 21 days' duration in patients suffering from infected eczematous dermatitis. The cream was applied twice daily (morning and evening) in a thin layer with or without light occlusive dressing. The onset of therapeutic efficacy was observed, on average, after 9.5 days; subjective signs and symptoms significantly improved during the trial (ANOVA P <0.001). Most patients (92{\%}) were completely cured in 21 days. Cosmetic acceptability of the cream was satisfactory. Only two patients dropped-out because of a severe burning sensation. No allergic reactions either with the ordinary patch test or the photopatch test were observed.",
author = "Pigatto, {P. D.} and M. Morelli and Altomare, {G. F.} and C. Borghi",
year = "1987",
language = "English",
volume = "24",
pages = "222--226",
journal = "Clinical Trials Journal",
issn = "0009-9325",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Halometasone/triclosan cream

T2 - (Sicorten plus). A study of clinical and allergological behaviour

AU - Pigatto, P. D.

AU - Morelli, M.

AU - Altomare, G. F.

AU - Borghi, C.

PY - 1987

Y1 - 1987

N2 - The clinical efficacy and safety, and the allergic potential of Sicorten Plus cream (0.05% halometasone, 1% triclosan) was investigated in an open trial of 21 days' duration in patients suffering from infected eczematous dermatitis. The cream was applied twice daily (morning and evening) in a thin layer with or without light occlusive dressing. The onset of therapeutic efficacy was observed, on average, after 9.5 days; subjective signs and symptoms significantly improved during the trial (ANOVA P <0.001). Most patients (92%) were completely cured in 21 days. Cosmetic acceptability of the cream was satisfactory. Only two patients dropped-out because of a severe burning sensation. No allergic reactions either with the ordinary patch test or the photopatch test were observed.

AB - The clinical efficacy and safety, and the allergic potential of Sicorten Plus cream (0.05% halometasone, 1% triclosan) was investigated in an open trial of 21 days' duration in patients suffering from infected eczematous dermatitis. The cream was applied twice daily (morning and evening) in a thin layer with or without light occlusive dressing. The onset of therapeutic efficacy was observed, on average, after 9.5 days; subjective signs and symptoms significantly improved during the trial (ANOVA P <0.001). Most patients (92%) were completely cured in 21 days. Cosmetic acceptability of the cream was satisfactory. Only two patients dropped-out because of a severe burning sensation. No allergic reactions either with the ordinary patch test or the photopatch test were observed.

UR - http://www.scopus.com/inward/record.url?scp=0023265202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023265202&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023265202

VL - 24

SP - 222

EP - 226

JO - Clinical Trials Journal

JF - Clinical Trials Journal

SN - 0009-9325

IS - 3

ER -